Joining a Parkinson’s clinical trial means volunteering for a structured research study — testing a new drug, device, exercise program, or surgical approach — under careful oversight by an ethics board and, for drug or device studies, by the FDA. According to the Michael J. Fox Foundation, there are consistently hundreds of Parkinson’s trials actively recruiting across the United States, and many can be found through the free Fox Trial Finder tool or through ClinicalTrials.gov, the federal registry maintained by the National Institutes of Health. Trials run in phases: Phase 1 checks safety in small groups, Phase 2 tests whether the treatment appears to work, and Phase 3 compares it against standard care or placebo in large groups before regulators consider approval. You may receive placebo rather than the active treatment, and you can withdraw at any time for any reason. Study-specific treatments and visits are generally paid by the sponsor. Trials need volunteers at all disease stages, including people with very early symptoms and people without Parkinson’s who serve as control participants in observational studies.

Not medical advice. This article is general information. Whether a specific trial is appropriate for you depends on your medical history, current treatments, and goals. Talk with your neurologist before enrolling. See our Medical Disclaimer.

What a Parkinson’s clinical trial actually is

A clinical trial is a structured research study that tests a medical question — a new drug, a new device, a new surgery, a new exercise program, or a new way to diagnose or monitor a disease. Trials are tightly regulated by ethics committees (institutional review boards) and, when drugs or devices are involved, by national agencies such as the FDA in the United States.

Trials follow a clear plan called a protocol, which describes who can participate, what will be done, what will be measured, and how participant safety will be protected. Volunteers are informed in detail before agreeing — this is called informed consent.

The phases of trials

Phase 1. Small studies in a small number of volunteers to evaluate safety and dosing. Often these are healthy volunteers, though in Parkinson’s some early trials enroll patients.
Phase 2. Larger studies in patients to test whether the treatment seems to work and at what dose, while continuing to monitor safety.
Phase 3. Large studies, often hundreds or thousands of patients across many sites, comparing the new treatment to standard of care or to placebo to confirm benefit and safety. This is the level of evidence regulators usually require for approval.
Phase 4. Studies done after approval to track real-world performance.

Not every trial is testing a brand-new drug. Many Parkinson’s trials test exercise programs, digital tools, surgical refinements, dietary interventions, or improved ways to use existing medications.

What kinds of trials exist in Parkinson’s

Treatment trials. New medications, new doses, new device-assisted therapies, deep brain stimulation refinements, gene therapies, or surgical procedures.
Disease-modification trials. Studies trying to slow or stop the underlying disease, often in early Parkinson’s.
Symptom-management trials. Better treatments for tremor, dyskinesia, off periods, hallucinations, sleep, mood, or balance.
Diagnostic and biomarker trials. Testing new ways to identify the disease earlier or more accurately.
Exercise and rehabilitation trials. Comparing different exercise programs, devices, or rehab approaches.
Observational studies. No new treatment — researchers track participants over time to understand how the disease evolves. These often need very large numbers of volunteers, including people without Parkinson’s.

Why participate?

You may gain access to a promising treatment before it’s widely available.
You’ll usually have extra medical monitoring during the study, sometimes at no cost.
Your participation directly contributes to the science.
You may help researchers improve quality of life for the next generation.

At the same time:

The treatment may not work — that’s what’s being tested.
You may receive placebo rather than the active treatment.
There may be side effects, including unexpected ones.
Visits, tests, and time commitment can be significant.
You may have to be off certain medications for parts of the study.

An honest weighing of these factors, in conversation with your neurologist and a study coordinator, is the right starting point.

How to find trials

ClinicalTrials.gov

The U.S. National Institutes of Health maintains a public registry of clinical trials at clinicaltrials.gov. You can search by condition (Parkinson’s disease), location, and recruitment status. Each entry includes eligibility criteria, contact information, and details about the study.

Fox Trial Finder

The Michael J. Fox Foundation runs a Parkinson’s-specific matching tool called Fox Trial Finder at foxtrialfinder.org. After a short profile, the tool suggests trials that may match.

Your neurologist or movement-disorder center

Academic medical centers and large neurology practices often run trials themselves and know which trials are recruiting nearby. Ask at your next appointment.

Patient advocacy organizations

The Parkinson’s Foundation, the American Parkinson Disease Association, and others maintain trial-finding resources and can help connect you with researchers.

Specific large studies

Some long-running studies — like the Parkinson’s Progression Markers Initiative (PPMI) — regularly recruit both people with Parkinson’s and people without.

What to expect from the process

Screening. Many trials have detailed eligibility criteria. A screening visit checks whether you meet them.
Informed consent. The team explains the study in detail, including risks, benefits, time commitment, alternatives, and your right to withdraw at any time. Read carefully and ask questions before signing.
Baseline visit. Initial measurements, exams, and questionnaires.
Study visits. Visits at regular intervals over weeks, months, or years. These may involve neurological exams, blood draws, imaging, walking tests, or symptom diaries.
End-of-study and follow-up. Measurements at the end, and sometimes follow-up to track long-term outcomes.

You can withdraw from a trial at any point, for any reason. Your usual medical care continues.

What questions to ask

What is being tested?
Will I receive placebo, and if so, with what likelihood?
Will I be able to continue my current Parkinson’s medications?
How many visits will there be, and how long will each take?
What tests and procedures will be done?
What are the known and possible risks?
What happens if I have a side effect — who pays for treatment?
Will I be reimbursed for travel, parking, or meals?
Will I be told what treatment group I was in after the study?
Will I be told the overall results?
If the treatment helps me, will I be able to continue receiving it after the study ends?
Who will see my data?
What is the role of the company sponsoring the study, if any?

Costs and payments

Study-specific treatments, tests, and visits are usually paid by the study sponsor.
Usual medical care (your regular Parkinson’s care, unrelated medical problems) is still billed to your insurance.
Some studies pay participants for time and travel; others don’t.
You should not be charged for the experimental treatment itself.

Risks and protections

Every trial is reviewed by an institutional review board (IRB) that evaluates risks and benefits.
Trials are monitored continuously; a Data Safety Monitoring Board may pause or stop a study if safety problems emerge.
You receive a copy of the informed-consent document, and you can ask for clarification at any time.
Confidentiality protections are described in the consent.

If you don’t qualify, or can’t travel

Look for observational studies. Many can be done remotely.
Register your interest with patient advocacy organizations — you may be contacted as new trials open.
Some trials offer reimbursement for travel; ask.

When to talk to your neurologist about trials

You’re interested in contributing to research.
You have early Parkinson’s and want to learn about disease-modification trials.
Your current treatment is no longer working well, and you want to explore new options.
You’ve identified a specific trial and want guidance on whether it’s appropriate.

Frequently asked questions

Are trials safe?

Trials are carefully regulated, with multiple safety layers — IRB review, ongoing monitoring, and informed consent. That said, all trials involve some risk, which is exactly why they’re being conducted. The trial team will explain the specific risks of each study.

Will I definitely get the experimental treatment?

Not necessarily. Many trials randomize participants to active treatment or placebo. The consent document will tell you the chance of being in each group.

Can I stay on my current medications?

Some trials require a “washout” of certain medications; others allow them. Eligibility criteria will say. Never stop a medication on your own to qualify for a trial — talk with both your neurologist and the study team.

What is “compassionate use”?

Compassionate use, or expanded access, is a separate pathway through which a patient with a serious condition may sometimes receive an experimental treatment outside a trial. It’s tightly regulated and requires the sponsor’s agreement. Your neurologist can advise.

Are there trials for people without Parkinson’s?

Yes. Observational studies often need control participants and family members. PPMI is one well-known example.

Sources

This article is general information only and is not medical advice. Please see our Medical Disclaimer and discuss specific trials with your neurologist.

How to Find and Join a Parkinson’s Clinical Trial